Last Updated : December 9, 2024
Details
FilesGeneric Name:
etrasimod
Project Status:
Complete
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Velsipity
Project Line:
Reimbursement Review
Project Number:
SR0795-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | December 08, 2023 |
|---|---|
| Call for patient/clinician input closed | February 12, 2024 |
| Clarification: - Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society | |
| Submission received | February 05, 2024 |
| Submission accepted | February 20, 2024 |
| Review initiated | February 21, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | May 14, 2024 |
| Deadline for sponsors comments | May 24, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | June 14, 2024 |
| Expert committee meeting (initial) | June 26, 2024 |
| Draft recommendation issued to sponsor | July 10, 2024 |
| Draft recommendation posted for stakeholder feedback | July 18, 2024 |
| End of feedback period | August 01, 2024 |
| Final recommendation issued to sponsor and drug plans | August 14, 2024 |
| Final recommendation posted | August 30, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | August 28, 2024 |
| CADTH review report(s) posted | December 04, 2024 |
Files
Last Updated : December 9, 2024